Unity Biotechnology (NASDAQ:UBX) Given New $4.00 Price Target at Chardan Capital

Posted by Linda Flegge on Mar 25th, 2025

Unity Biotechnology (NASDAQ:UBX – Get Free Report) had its target price cut by research analysts at Chardan Capital from $6.00 to $4.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target points to a potential upside of 207.69% from the company’s current price.

Separately, HC Wainwright dropped their price target on Unity Biotechnology from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Monday.

View Our Latest Stock Analysis on UBX

Unity Biotechnology Stock Performance

Shares of NASDAQ UBX opened at $1.30 on Tuesday. The stock has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.51. The firm has a market capitalization of $21.93 million, a price-to-earnings ratio of -0.99 and a beta of 1.02. Unity Biotechnology has a 52-week low of $0.94 and a 52-week high of $3.10.

Hedge Funds Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC raised its position in Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 100.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned approximately 0.30% of Unity Biotechnology worth $49,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 29.49% of the company’s stock.

About Unity Biotechnology

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.